Introduction {#s1}
============

Glaucoma is an optic neuropathy characterized by the thinning of the retinal nerve fiber layer (RNFL) and an increase of optic disc cupping ([@B22]; [@B32]). It is one of the leading causes of irreversible blindness, if not properly detected and managed ([@B11]). The therapeutic strategy used by ophthalmologists for primary open-angle glaucoma (POAG) is to lower intraocular pressure (IOP) by using drugs, laser, or surgical therapy ([@B29]; [@B8]; [@B13]; [@B3]). Despite a significant reduction of IOP, many cases defined as "well controlled" show a disease progression ([@B28]). Moreover, it has been demonstrated that glaucoma not only affects the optic nerve but also involves all the visual pathways, causing, in the later stages, changes in geniculate lateral nucleus (GLN) and visual cortex ([@B6]). These considerations have led or lead to new definitions of glaucoma and to new perspectives in POAG therapy ([@B7]). Neuroprotection represents a new chapter in the disease treatment, intended to preserve structures and functions of the visual system ([@B23]; [@B30]). Several molecules have neuroprotective properties, and, among them, citicoline (CT) appears to be very interesting and has been tested in different studies ([@B17]; [@B35]; [@B25]; [@B27]; [@B30]).

CT is a nucleotide formed by ribose, cytosine, pyrophosphate, and choline, which play a crucial role in the synthesis of phospholipids, particularly glycerophospholipid phosphatidylcholine ([@B26]; [@B27]). Phospholipids are the main components of the cell membrane, as they guarantee the structural integrity of cells and are the fundamental compound for several enzymes ([@B2]). After oral administration, CT is hydrolyzed, in the intestinal wall, to choline and cytidine, and then the latter is converted to uridine ([@B2]; [@B25]; [@B34]). After absorption, these compounds reach the central nervous system (CNS) where CT can be restored by the CTP-phosphocholine cytidylyltransferase enzyme ([@B2]; [@B5]; [@B25]; [@B34]).

Glaucomatous patients present neural transmission delay in the GLN ([@B17]; [@B35]). The afferent axon of retinal ganglion cell releases neurotransmitters in the inter-synaptic space, activating the GNL's cells, which in turn develop the ganglion cell's axon, relaxing neurotrophic factors ([@B33]). A trans-synaptic dysfunction at this level is a consequence of retinal ganglion cell loss in glaucoma ([@B7]). CT acts on this dysfunction through its neuroprotective and neuro-enhancement properties, thanks to both its neuro-modulatory action on the dopaminergic system and the synthesis of phospholipids ([@B26]; [@B25]). Three previously published papers have shown that in glaucoma patients, CT treatment improves the retinal bioelectrical responses and the activity of the visual cortex, slowing down the glaucomatous rates of progression ([@B20]; [@B18]; [@B21]).

Herein, we evaluate both functional \[standard automated white-on-white perimetry (SAP)\] and morphological \[optical coherence tomography (OCT)\] parameters in glaucomatous patients treated with orally administered CT.

Methods {#s2}
=======

This prospective study included 84 glaucoma patients randomly divided into two groups (groups A and B), with similar age, sex, disease duration, and disease stage, who had been referred to the Glaucoma Unit of University of Molise, Campobasso (Italy), on starting neuroprotective co-adjuvant treatment. The study was performed in accordance with the ethical standards stated in the 1964 Declaration of Helsinki and approved by the local clinical research ethics committee. Informed consent was obtained from all subjects after being given a detailed description of the objectives of the study and the procedure to be used. Investigations were conducted in accordance with Good Clinical Practice (GCP). POAG diagnosis and classification were based on the Glaucoma Staging System (GSS) ([@B1]). Patients selected for this study had shown a SAP mean deviation (MD) reduction ranging between 1 and 1.5 db/year during the previous 2 years, although IOP had apparently stablilized with therapy \[≤18 mmHg measured with Goldmann applanation tonometry (GAT)\]. All patients underwent a complete eye examination, including IOP measurement with GAT, gonioscopy, ophthalmoscopy, central corneal thickness (CCT) measurement with a Scheimpflug camera-based device (Oculus Pentacam, Wetzlar, Germany), SAP, and RNFL and ganglion cell complex (GCC) evaluation with OCT (RTVue, Optovue, Freemont, CA, USA). GAT was always performed in the afternoon, between 2 p.m. and 4 p.m.; SAP was performed with a Humphrey Field Analyzer (HFAII, Carl Zeiss Meditec, Dublin, CA, USA), with a size III stimulus, Swedish interactive threshold algorithm (SITA) standard, and 30-2 pattern. Each glaucoma patient referring to both units underwent SAP every 6 months, so they were used to the procedure. Moreover, only exams with good reliability indices (with less than 33% fixation losses or false-negative errors, or less than 15% false-positive errors) were included in the study for statistical evaluation. To reduce operator-related bias, physicians were not aware of any subsequent CT treatment. Lowering topical therapy included 0.5 mg of timolol (11, 37%), travoprost 0.004% (10, 33%), and fixed combination of 0.3 mg of bimatoprost and 0.5 mg of timolol (9, 30%). During the follow-up period, no IOP spikes occurred, with a mean IOP increase of no more than 3 mmHg at every check ([**Table 1**](#T1){ref-type="table"}).

###### 

Means and standard deviation (SD) of intraocular pressure values in groups A and B during the evaluated follow-up with statistical evaluation of differences.

                Baseline   6 months' follow-up   *p* value   12 months' follow-up   *p* value   18 months' follow-up   *p* value   24 months' follow-up   *p* value
  ------------- ---------- --------------------- ----------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
  Group A                                                                                                                                                 
  Mean (mmHg)   13.83      14.1                  0.34        13.6                   0.19        14.33                  0.11        14.07                  0.43
  SD            1.34       1.09                              1.57                               1.37                               1.2                    
  Group B                                                                                                                                                 
  Mean (mmHg)   14.3       14.0333               0.37        14.08                  0.23        14.2                   0.64        14.3                   0.41
  SD            1.15       1.25                              1.315                              1.3                                2.04                   
  *p* value     0.15       0.82                              0.21                               0.63                               0.59                   

Included patients were randomly divided into two groups: Group A received CT oral solution (Neukron Ofta; Omicron, Rome, Italy), whereas group B did not receive any oral treatment. CT posology was one vial (500 mg of CT in 10 mL of oral solution) per day for 4 months, followed by a 2-month interruption, after which the therapy cycle was repeated again for another 6 months, as suggested by the manufacturer; this cycle of administration is displayed in [**Figure 1**](#f1){ref-type="fig"}. Exclusion criteria were as follows: inability to perform SAP, best corrected visual acuity (BCVA) worse than 20/40, significant ocular media opacities, a history of previous glaucoma surgery, cataract or retinal surgery, and concomitance of ocular diseases that might bias SAP performance or results. Concomitance with systemic diseases that might lead to visual acuity damage or affect SAP execution, low quality (\<35) in OCT scans, contraindications, and/or intolerance to CT were also considered as exclusion criteria. Lastly, patients with pseudoexfoliative glaucoma and/or pigmentary glaucoma were also excluded.

![Citicoline therapy cycles for 1-year treatment.](fphar-10-01117-g001){#f1}

Every 6 months, both groups underwent a complete eye visit, SAP, and OCT scans. In addition, in group A, CT therapy adherence and any side effects were evaluated at each check. At the beginning of the study, each group consisted of 42 patients. During the follow-up, some patients had been excluded because of interruptions of the neuroprotective treatment, changes in IOP-lowering therapy, or the need for ocular surgery or they were lost to follow-up. Only the data of patients of both groups who completed the 2-year evaluations without meeting any exclusion criteria were compared and statistically analyzed at 6, 12, 18, and 24 months' follow-up.

Demographic characteristics and values obtained by SAP and OCT in both groups of participants at baseline are summarized in [**Table 2**](#T2){ref-type="table"}. GSS 2 classification of eyes included in the study is summarized in [**Table 3**](#T3){ref-type="table"}.

###### 

Group parameters at baseline.

  Parameter                   Group A   Group B   P              
  --------------------------- --------- --------- ------- ------ -------
  Age (years)                 64.1      5.8       62.9    7.2    0.465
  Sex ratio (M/F)             16/14     16/14                    
  Disease duration (months)   38.73     1.53      35.53   1.65   0.929
  MD (dB)                     −6.51     2.65      −6.39   2.03   0.850
  RNFL (µm)                   72.9      7.3       73.3    4.9    0.785
  RNFL Sup (µm)               86.2      7.3       87.4    5.9    0.515
  RNFL Inf (µm)               94.6      7.5       95.4    6.9    0.673
  RNFL Nas (µm)               70.8      8.8       68.7    6.5    0.305
  RNFL Temp (µm)              68.1      8.9       66.3    6.5    0.373
  GCC (µm)                    73.8      7.5       74.6    5.2    0.626
  GCC Sup (µm)                75.6      7.7       75.9    5.4    0.839
  GCC Inf (µm)                71.9      8.0       73.2    5.3    0.457

Statistical comparison of demographical data and optic nerve parameters in group A (patients assuming citicoline) and group B (controls), before starting therapy with citicoline. MD, mean deviation measured with standard automatic perimetry (SAP); RNFL, overall retinal nerve fiber layer thickness; RNFL Sup, superior retinal nerve fiber layer thickness; RNFL Inf, inferior retinal nerve fiber layer thickness; RNFL Nas: nasal retinal nerve fiber layer thickness; RNFL Temp, temporal retinal nerve fiber layer thickness; GCC, overall ganglion cell complex thickness; GCC Sup, superior ganglion cell complex thickness; GCC Inf, inferior ganglion cell complex thickness measured with ocular coherence tomography (OCT); p: Student t-test significance.

###### 

Staging of the eyes included in the study.

  Glaucoma staging system 2    Group A   Group B       
  ---------------------------- --------- --------- --- ----
  Generalized defect stage 1   3         10        7   23
  Generalized defect stage 2   6         20        6   20
  Generalized defect stage 3   1         3         1   3
  Mixed defect stage 1         4         13        2   7
  Mixed defect stage 2         9         30        7   23
  Mixed defect stage 3         6         20        7   23
  Localized defect stage 1     1         3         0   0

Classification of eyes included in the study, in groups A and B, according to Glaucoma Staging System 2.

Parameters evaluated were as follows: MD and standard deviation (SD) measured with SAP; RNFL total thickness (RNFL); superior (RNFL Sup), inferior (RNFL Inf), temporal (RNFL Temp), and nasal (RNFL Nas) quadrant thickness; and GCC overall thickness (GCC), superior (GCC Sup), and inferior (GCC Inf) hemifield thickness measured with OCT. Even if every patient had bilateral POAG, only one eye per patient was randomly included in the statistical analysis, in order to reduce intra-subjective bias.

Statistical Evaluation {#s3}
======================

The fulfillment of the data requirements for parametric analysis (normality and homogeneity of variance) was assessed by specific tests (Kolmogorov--Smirnov and Levene). For all parameters, a preliminary separate two-way repeated-measures analysis of variance (ANOVA) was carried out, with treatment as between-group factor and time as repeated-measures factor. Based on significant results for time effect (*p* \< 0.001) and time × treatment interaction effect (*p* \< 0.001) of previous analysis, groups A and B were compared with one-way factorial ANOVA for each parameter. In addition, intra-group time variation of parameters was evaluated with Student's *t*-test for repeated measures. Finally, the correlations between baseline measures and their variations after 24 months were evaluated using the parametric (Pearson) test. For all tests, the level of significance was set at *p* \< 0.05. All analyses were performed using SPSS software (IBM Corp. Armonk, New York) version 18.0.

Results {#s4}
=======

At the beginning of the study, the IOP values of group A, measured with GAT, always between 2 p.m. and 4 p.m., ranged between 12 and 16 mmHg (mean: 13.83 ± 1.34 mmHg), and the IOP values of group B ranged between 12 and 16 mmHg IOP (mean: 14.3 ± 1.15 mmHg). After 2 years, the complete data record referred to 30 patients for each group; nine patients were excluded because of interruption of CT treatment and eight because of changes in IOP-lowering treatment, and seven were lost to follow-up.

Over the follow-up period, patients in group A showed significantly higher values of MD measured with SAP than did those recorded in patients of group B (at 18 months, *p* \< 0.039; and at 24 months, *p* \< 0.006) ([**Figure 2**](#f2){ref-type="fig"}). Overall RNFL thickness values measured in group A were statistically higher than those in group B at 12 (*p* \< 0.007), 18 (*p* \< 0.0001), and 24 months (*p* \< 0.0001) of follow-ups ([**Figure 3**](#f3){ref-type="fig"}). By analyzing RNFL thickness variations in more detail, it is possible to observe that superior and inferior zones showed statistically higher values in group A eyes compared with group B after only 12 months' follow-up. In contrast, in nasal and temporal sectors, the differences between RNFL thickness measured in both groups showed statistically higher values in group A eyes starting at 6 months' follow-up ([**Figure 4**](#f4){ref-type="fig"}). In addition for GCC, it was possible to observe that, overall, both superior and inferior thickness showed significantly higher values at 12 (*p* \< 0.003), 18 (*p* \< 0.0001), and 24 months (*p* \< 0.0001) of follow-ups ([**Figure 4**](#f4){ref-type="fig"}). In group A, fewer variations of all parameters at each follow-up were recorded, and these variations were statistically less significant than those observed in group B ([**Table 4**](#T4){ref-type="table"}). In group A, only a slight correlation between MD and RNFL values before starting the study and their variations observed during the following 24 months was observed. In group B, each evaluated parameter---except for GCC Inf---showed a statistically significant correlation between values measured at baseline and the decrease observed during 2 years' follow-up ([**Table 5**](#T5){ref-type="table"}). Altogether, these data suggest that in group A, the CT treatment effect did not depend on the stage of the disease, whereas in group B, the eyes showed that the occurrence or not of improvement was related to the stage of the disease. No side effect of CT treatment was reported during the whole follow-up period. No statistical difference (*p* = 0.49) in CCT, measured at the start of the study, was observed between group A eyes (mean: 523.73 ± 8.4 µm) and group B eyes (mean: 525.07 ± 6.14 µm).

![Scatterplot showing mean deviation (MD) values measured (decibel) with standard automated white-on-white perimetry (SAP), on the vertical axis, in patients assuming citicoline (gray boxes) and in patients not undergoing therapy with citicoline (black circle), before starting therapy (BT), at 6 months' follow-up (FU 6), at 12 months' follow-up (FU 12), at 18 months' follow-up (FU 18), and at 24 months' follow-up (FU 24). *p* values mean significant differences (*t*-test).](fphar-10-01117-g002){#f2}

![Comparison of overall retinal nerve fiber layer (RNFL) thickness values measured (microns) with ocular coherence tomography (OCT), on the vertical axis, in patients assuming citicoline (white column) and in patients not undergoing therapy with citicoline (grey column), before starting therapy (BT), at 6 months' follow-up (FU 6), at 12 months' follow-up (FU 12), at 18 months' follow-up (FU 18), and at 24 months' follow-up (FU 24). *p* values mean significant differences (*t*-test).](fphar-10-01117-g003){#f3}

![Comparison of RNFL thickness values measured (microns) in different sectors (**A**: superior; **B**: inferior; **C**: nasal; **D**: temporal) with ocular coherence tomography (OCT), on the vertical axis, in patients assuming citicoline (white column) and in patients not undergoing therapy with citicoline (grey column), before starting therapy (BT), at 6 months' follow-up (FU 6), at 12 months' follow-up (FU 12), at 18 months' follow-up (FU 18), and at 24 months' follow-up (FU 24). *p* values mean significant differences (*t*-test).](fphar-10-01117-g004){#f4}

###### 

Parameter analysis of both groups over the follow-ups.

  Paired Student's *t*-test comparison                                                                          
  -------------------------------------- ---------------- -------- ----------- ----------- -------- ----------- -----------
  MD                                     0 vs. 6 months   −0.496   12.690      **0.001**   −0.751   12.028      **0.001**
  6 vs. 12 months                        −0.131           1.620    0.116       −0.816      12.827   **0.001**   
  12 vs. 18 months                       −0.119           2.200    **0.036**   −0.682      10.784   **0.001**   
  18 vs. 24 months                       −0.064           1.316    0.199       −0.639      9.531    **0.001**   
  RNFL                                   0 vs. 6 months   −1.738   9.166       **0.001**   −5.030   20.137      **0.001**
  6 vs. 12 months                        −0.741           5.680    **0.001**   −3.362      4.920    **0.001**   
  12 vs. 18 months                       −0.276           2.692    0.012       −4.476      37.065   **0.001**   
  18 vs. 24 months                       −0.144           2.468    0.020       −4.676      37.439   **0.001**   
  RNFL Sup                               0 vs. 6 months   −1.594   9.114       **0.001**   −4.500   16.430      **0.001**
  6 vs. 12 months                        −0.748           5.478    **0.001**   −4.055      28.439   **0.001**   
  12 vs. 18 months                       −0.277           2.445    0.021       −4.491      35.957   **0.001**   
  18 vs. 24 months                       −1.396           2.524    0.017       −4.858      52.242   **0.001**   
  RNFL Inf                               0 vs. 6 months   −1.504   11.967      **0.001**   −4.511   25.876      **0.001**
  6 vs. 12 months                        −0.749           7.200    **0.001**   −4.245      22.547   **0.001**   
  12 vs. 18 months                       −0.213           2.151    **0.040**   −4.542      35.663   **0.001**   
  18 vs. 24 months                       −0.225           2.633    **0.013**   −4.811      43.296   **0.001**   
  RNFL Nas                               0 vs. 6 months   −1.595   8.190       **0.001**   −4.530   21.142      **0.001**
  6 vs. 12 months                        −0.815           5.591    **0.001**   −4.160      27.324   **0.001**   
  12 vs. 18 months                       −0.176           2.215    **0.035**   −4.273      29.209   **0.001**   
  18 vs. 24 months                       −0.252           2.510    **0.018**   −4.865      38.397   **0.001**   
  RNFL Temp                              0 vs. 6 months   −1.843   11.391      **0.001**   −4.538   21.436      **0.001**
  6 vs. 12 months                        −0.726           5.899    **0.001**   −3.808      19.414   **0.001**   
  12 vs. 18 months                       −0.147           0.929    0.361       −4.319      24.487   **0.001**   
  18 vs. 24 months                       −0.170           2.255    **0.032**   −4.661      52.818   **0.001**   
  GCC                                    0 vs. 6 months   −1.532   10.125      **0.001**   −4.541   22.862      **0.001**
  6 vs. 12 months                        −1.058           6.648    **0.001**   −4.552      20.706   **0.001**   
  12 vs. 18 months                       −0.162           2.290    **0.029**   −4.472      37.441   **0.001**   
  18 vs. 24 months                       −0.146           2.579    **0.015**   −4.928      39.883   **0.001**   
  GCC Sup                                0 vs. 6 months   −1.149   7.218       **0.001**   −3.877   14.240      **0.001**
  6 vs. 12 months                        −0.874           5.306    **0.001**   −3.987      18.143   **0.001**   
  12 vs. 18 months                       −0.270           2.573    **0.015**   −4.328      22.581   **0.001**   
  18 vs. 24 months                       −0.164           2.368    **0.025**   −4.785      40.536   **0.001**   
  GCC Inf                                0 vs. 6 months   −1.329   2.467       **0.020**   −5.268   18.620      **0.001**
  6 vs. 12 months                        −1.319           3.200    **0.003**   −5.101      11.989   **0.001**   
  12 vs. 18 months                       −0.383           2.604    **0.014**   −4.628      25.836   **0.001**   
  18 vs. 24 months                       −0.205           1.535    0.136       −5.026      31.681   **0.001**   

Statistical analysis of the differences between evaluated parameters from baseline to 24 months' follow-up. MD, mean deviation measured with standard automatic perimetry (SAP); RNFL, overall retinal nerve fiber layer thickness; RNFL Sup, superior retinal nerve fiber layer thickness; RNFL Inf, inferior retinal nerve fiber layer thickness; RNFL Nas, nasal retinal nerve fiber layer thickness; RNFL Temp, temporal retinal nerve fiber layer thickness; GCC: overall ganglion cell complex thickness; GCC Sup, superior ganglion cell complex thickness; GCC Inf, inferior ganglion cell complex thickness measured with ocular coherence tomography (OCT). p, Paired Student t-test significance (values \< 0.05 in bold; values \< 0.005 in bold on gray).

###### 

Analysis of correlation between studied parameter values at baseline and variations of the same parameters during follow-up in both groups, in order to evaluate if baseline values influence the variations detected.

                                    Var 0−24%   
  ----------- --------------------- ----------- -----------
  MD          Pearson correlation   0.406       0.757
              Sig. (2-tailed)       **0.026**   **0.000**
              N                     30          30
  RNFL        Pearson correlation   0.374       0.540
              Sig. (2-tailed)       **0.042**   **0.002**
              N                     30          30
  RNFL Sup    Pearson correlation   −0.021      0.728
              Sig. (2-tailed)       0.912       **0.000**
              N                     30          30
  RNFL Inf    Pearson correlation   0.036       0.588
              Sig. (2-tailed)       0.849       **0.001**
              N                     30          30
  RNFL Nas    Pearson correlation   0.037       0.795
              Sig. (2-tailed)       0.846       **0.000**
              N                     30          30
  RNFL Temp   Pearson correlation   0.029       0.619
              Sig. (2-tailed)       0.880       **0.000**
              N                     30          30
  GCC         Pearson correlation   0.089       0.467
              Sig. (2-tailed)       0.639       **0.009**
              N                     30          30
  GCC Sup     Pearson correlation   0.067       0.421
              Sig. (2-tailed)       0.726       **0.021**
              N                     30          30
  GCC Inf     Pearson correlation   −0.239      0.336
              Sig. (2-tailed)       0.204       0.069
              N                     30          30

Correlation analysis between the variations of the optic nerve parameters evaluated at the beginning of the study and the values observed after 24 months. MD, mean deviation measured with standard automatic perimetry (SAP); RNFL, overall retinal nerve fiber layer thickness; RNFL Sup, superior retinal nerve fiber layer thickness; RNFL Inf, inferior retinal nerve fiber layer thickness; RNFL Nas, nasal retinal nerve fiber layer thickness; RNFL Temp, temporal retinal nerve fiber layer thickness; GCC, overall ganglion cell complex thickness; GCC Sup, superior ganglion cell complex thickness; GCC Inf, inferior ganglion cell complex thickness measured with ocular coherence tomography (OCT). p, Pearson correlation significance (values \< 0.05 in bold; values \< 0.005 in bold on gray).

IOP value evaluations showed no intra-group significant difference during the follow-up in both groups.

Discussion {#s5}
==========

Co-adjuvant neuroprotective treatment with oral CT in glaucoma patients has shown promising results, thanks to both neuroprotective and neuro-enhancement properties ([@B25]; [@B4]; [@B34]; [@B24]). Previously published studies have evaluated the efficacy of CT on the visual field or electrophysiology ([@B31]; [@B19]; [@B20]; [@B18]; [@B21]). In this study, OCT has been utilized jointly with SAP to evaluate changes in RNFL and GCC, since, in recent years, this diagnostic approach has been proven to be more relevant in glaucoma diagnosis and management ([@B9]; [@B12]; [@B15]; [@B16]; [@B10]; [@B14]). The differences observed in this study may depend on therapy adherence. In fact, if daily therapy is not well followed, it may produce spikes in IOP that lead to a worsening of retinal sensitivity (documented by SAP) and to a thinning of RNFL (measured with OCT). Patients enrolled in the study were always asked about therapy compliance, which proved to be appropriate. It is important to remember that patients whose tests showed IOP spikes at any of the follow-up checks, and who thus required additional therapy or surgery, were subsequently excluded from this study.

Data observed in this study suggest that CT has an effect in slowing the MD reduction measured with SAP after 18 months ([**Figure 2**](#f2){ref-type="fig"}) of therapy and that this effect appears to be stable in the following 6 months ([**Figure 2**](#f2){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}). It is interesting to note that this effect was not so evident at 6 and 12 months' follow-up, thereby suggesting that this type of treatment needs time to show relevant clinical results.

Topical CT eye drops have been showed to have a positive effect in glaucoma patients, detected by pattern electroretinogram (PERG) and visual-evoked potentials (VEPs) ([@B21]) after 4--6 months. This could suggest that electrophysiology devices are more sensitive in detecting CT-induced changes than are devices used in this study (SAP and OCT). In this study, oral medication has been investigated because it could be an easier option for patients, more for glaucoma patients who are usually older and have other different eye drops to take as medications, and instrumentations routinely used in glaucoma units confirmed the positive effect of this treatment. The advantage of using the oral solution is related to the compliance of the patients. To determine which between oral and topical CT has the best and faster effect is hard, because there are not so many studies investigating this topic, and none compared the two kinds of intake between them, but this could be the objective of a new prospective study. The important message of this study is that also oral CT has been proven to be effective in slowing optic nerve damage progression in glaucoma patients.

The analysis of overall RNFL changes indicated that the overall thinning is significantly slower after 12 months' follow-up ([**Figures 3**](#f3){ref-type="fig"} and [**4**](#f4){ref-type="fig"}) and it appears to be stable in the following 12 months ([**Figures 3**](#f3){ref-type="fig"} and [**4**](#f4){ref-type="fig"}; [**Table 4**](#T4){ref-type="table"}). Overall, superior and inferior GCC thickness showed similar behaviors during the time of observation ([**Figure 5**](#f5){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}). Interestingly, temporal and nasal RNFL thickness of group A showed significantly (*p* \< 0.05) higher values, than did those of group B, after 6 months of treatment. According to these data, OCT seems to be more sensitive in detecting the neuroprotective effect provided by oral CT treatment, highlighting it 6 months before SAP. In particular, temporal and nasal RNFLs show higher sensitivity than all other parameters provided by OCT. Moreover, in this study, no significant correlation was observed between SAP and OCT parameters evaluated at baseline and their variations during follow-up ([**Table 5**](#T5){ref-type="table"}). This is a very interesting outcome, because, if confirmed by further studies, it suggests that CT therapy is useful at every stage of glaucoma.

![Comparison of overall ganglion cell complex thickness values and the ones measured (microns) in different sectors (**A**: overall; **B**: superior; **C**: inferior) with ocular coherence tomography (OCT), on the vertical axis, in patients assuming citicoline (white column) and in patients not undergoing therapy with citicoline (grey column), before starting therapy (BT), at 6 months' follow-up (FU 6), at 12 months' follow-up (FU 12), at 18 months' follow-up (FU 18), and at 24 months' follow-up (FU 24). *p* values mean significant differences (*t*-test).](fphar-10-01117-g005){#f5}

One of the limitations of this study consists in the heterogeneity of the glaucoma stage in the patients enrolled, since the study was not limited to middle-stage glaucoma. On the other hand, this characteristic provides a more realistic representation of the population of patients usually referring to glaucoma units. The data analyzed in this study come from the evaluations routinely performed in the glaucoma unit. It is important to note that this is a prospective, randomized, comparative study and that this may, therefore, be considered a strength of this analysis. In order to improve this study, it would be useful to add new optic nerve testing devices to this protocol, and such devices will certainly be added to any future studies by this group.

Another limitation of the study is the small sample analyzed; it is very difficult to collect data on patients with the required characteristics in one glaucoma unit and evaluate them for 2 years. It is hoped that this study will encourage future research with larger study populations.

The findings of this study agree with the ones published by Parisi et al. and Ottobelli et al. ([@B20]; [@B18]; [@B21]), but our work provides a deeper analysis of optic nerve structures, by exploring the variation of RNFL and GCC. Previous studies on CT therapy effects have often been hard to compare due to the differences in the dosage, means of administration, and duration of therapy ([@B31]; [@B5]; [@B23]; [@B19]; [@B3]; [@B4]; [@B24]; [@B30]). This study, prescribing a new formulation specifically designed for glaucoma patients, is able to demonstrate data safely and easily reproducible in every kind of practice. Frequently, one of the most important factors causing low compliance in this kind of treatment is the CT administration mode ([@B5]; [@B4]). In contrast, here, the vial, following the manufacturer regimen, was well tolerated by the patients.

This study highlights a very interesting aspect of oral CT treatment: The effects are not visible rapidly. More than 1 year is needed to detect significant changes in MD ([**Figure 2**](#f2){ref-type="fig"}); therefore, physicians should support the idea of extending this therapy for longer than they usually do. OCT is able to highlight significant variations faster than other devices ([**Table 4**](#T4){ref-type="table"}), but it still requires months-long period. In conclusion, although these results need to be confirmed by further studies with a longer follow-up period and performed on a larger population, the data recorded confirm that CT administrated as an oral solution is effective in slowing the progression of POAG at different stages of the disease.
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